Related Experiment Video
Updated: May 12, 2026
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Consensus guidelines for the management and treatment of neuroendocrine tumors
Pamela L Kunz1, Diane Reidy-Lagunes, Lowell B Anthony
1Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305-5826, USA pkunz@stanford.edu
Abstract:
Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic locations. The management of this disease poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. The recent completion of several phase 3 trials, including those evaluating octreotide, sunitinib, and everolimus, demonstrate that rigorous evaluation of novel agents in this disease is possible and can lead to practice-changing outcomes. Nevertheless, there are many aspects to the treatment of neuroendocrine tumors that remain unclear and controversial. The North American Neuroendocrine Tumor Society published a set of consensus guidelines in 2010, which provided an overview for the treatment of patients with these malignancies. Here, we present a set of consensus tables intended to complement these guidelines and serve as a quick, accessible reference for the practicing physician.
Insights
Neuroendocrine tumors (NETs) are challenging to manage due to varied presentations. New consensus tables offer a quick reference to complement 2010 guidelines for practicing physicians.
Area of Science:
- Oncology
- Endocrinology
- Tumor Biology
Background:
- Neuroendocrine tumors (NETs) present a significant management challenge due to their heterogeneity and variable aggressiveness.
- Recent phase 3 trials with novel agents like octreotide, sunitinib, and everolimus highlight the possibility of practice-changing outcomes in NETs.
- Despite advances, many treatment aspects for NETs remain unclear and controversial.
Framework:
- Complements the 2010 North American Neuroendocrine Tumor Society (NA-NETS) consensus guidelines.
- Provides a set of consensus tables for accessible clinical reference.
- Aims to aid practicing physicians in managing neuroendocrine tumors.
Implementation:
- Focuses on providing practical, readily available information.
- Designed to bridge gaps in current understanding and controversial areas of NET treatment.
- Facilitates informed decision-making for patient care.
Implications:
- Enhances the clinical utility of existing guidelines for neuroendocrine tumors.
- Supports evidence-based practice in a complex oncologic field.
- Aims to improve patient outcomes through clearer management strategies.
